Manmeet Ahluwalia, M.D., co-principal investigator, of the Cleveland Clinic's Brain Tumor and Neuro-Oncology Center, added, "SRS is an effective first-line treatment for patients with metastatic brain cancer. However, for patients with recurrent disease that may not be appropriate for additional SRS or surgical resection, the LAASR study results indicate that LITT can be an effective option."
Monteris is exclusively focused on advancing both LITT technology and clinical research to serve the unmet needs of neurosurgeons and their patients. The company's NeuroBlate® System is a minimally invasive, MRI-guided laser ablation tool for brain lesions, including brain tumors and epileptic foci. In addition to its recently published LAASR study, the Monteris commitment to high quality clinical data is continuing with its LAANTERN2 prospective, multi-center registry that has enrolled over 300 patients.
Ad Statistics
Times Displayed: 124471
Times Visited: 7225 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Martin J. Emerson, president and CEO of Monteris Medical, commented, "The Monteris Medical team is proud to have supported this first-of-its-kind prospective, multi-center clinical trial for the treatment of metastatic brain tumors with LITT. We appreciate the commitment of the physician investigators and their research teams who were involved in LAASR, as we fully recognize the critical importance of key opinion leader collaboration in developing and establishing new minimally invasive options for patients."
Monteris Medical will be exhibiting at the Society for Neuro-Oncology annual meeting in New Orleans, Nov. 15-18. Visit booth 101 to see a full demonstration of the NeuroBlate System.
About Monteris® and the NeuroBlate® System
Monteris Medical is a privately held company that develops and markets innovative MRI-guided, laser-based systems for the ablation of brain lesions. Current investors include Versant Ventures, SightLine Partners, Birchview Capital and BDC Capital. The Monteris NeuroBlate® System, including the Mini-Bolt, is the only minimally invasive cranial access system that enables a robotic interface for the precise and safe delivery of laser energy. The NeuroBlate® System is a tool (as opposed to a "treatment") and is not intended to treat any specific disease. Physicians should use their clinical judgment and experience when deciding whether to use NeuroBlate®.
Back to HCB News
